SK Biopharmaceuticals Announces Organizational Reorganization and Executive Appointments for 2024
On the 7th of January, SK Biopharmaceuticals, under the leadership of CEO Lee Dong-hoon, unveiled an organizational reorganization and executive personnel appointments for the year 2024. This strategic move follows a comprehensive report presented to the board of directors.
As part of the reorganization, the Research and Development (R&D) department has shifted towards an agile project-oriented organizational structure, in contrast to the previous organization-oriented system. Notably, the establishment of a ‘Global Research and Development Committee’ aims to facilitate collaborative research initiatives between SK Biopharmaceuticals and its subsidiary, SK Life Science Labs, which focuses on local research in the United States. Furthermore, the company seeks to further develop key platforms such as protein degradation to target, radiopharmaceutical, and cell gene therapy.
Integration and Strategic Appointments
SK Biopharmaceuticals merged the business development team and the strategic investment team under the business development division. As a result, Team Leader Choi Yun-jeong, previously in charge of the strategic investment team, has been promoted to the position of Head of the Business Development Division. Notably, Choi Yoon-jeong, the newly appointed head of the business development department, is the third generation of the SK Group founder and the eldest daughter of SK Group Chairman Choi Tae-win. She represents the youngest executive in the SK Group’s latest reorganization.
An official from SK Biopharmaceuticals emphasized that the organizational reorganization and personnel appointments were carried out with the aim of enhancing research and development efficiency, flexibility, and collaboration. The overarching goal is to maximize synergy between the business development and strategic investment functions within the company.
Choi Yoon-jeong, Head of Business Development Division / Photo = SK Biopharm
SK Biopharmaceuticals (CEO Lee Dong-hoon) announced on the 7th that it has carried out an organizational reorganization and executive personnel appointments in 2024 following a report to the board of directors.
According to the company, research and development (R&D) has adopted an agile project-oriented organizational system rather than the current organization-oriented one. A ‘Global Research and Development Committee’ was established to promote joint research between SK Biopharmaceuticals and SK Life Science Labs, a subsidiary focused on local research in the United States, and continued to develop platforms (protein degradation has to target, radiopharmaceutical, and cell gene therapy). intend to expand.
SK Biopharmaceuticals integrated the business development team and the strategic investment team under the business development division, and Team Leader Choi Yun-jeong, who led the current strategic investment team, was promoted to the new head of the business development division. Choi Yoon-jeong, the new head of the business development department, is the third generation of the founder of SK Group and the eldest daughter of SK Group Chairman Choi Tae-win. Director Choi is known to be the youngest executive in this SK Group reorganization.
An official from SK Biopharmaceuticals said, “We carried out this organizational reorganization and personnel reorganization to strengthen research and development efficiency, flexibility and collaboration, and to maximize synergy between business development and strategic investment.”
#Biopharmaceuticals #reorganization #reorganization #executive #personnel.. #Choi #Yoonjeong #youngest #executive #3rd #generation #entrepreneur
